For instance, hypophysitis is more prevalent following treatment with anti-CTLA-4 drugs like ipilimumab, while thyroid dysfunction is more commonly associated with anti-PD-1 drugs such as nivolumab and pembrolizumab. This evidence concerns the gene CTLA4 and hypophysitis.